Skip to main content

Table 3 HZ mortality data from included studies

From: Herpes zoster-associated mortality in Europe: a systematic review

Study (ref)

Country

Period

Age (years)

Age at HZ-related death

Mortality incidence/100 000 (95% CI)

Case fatality rate (%)

Hospital fatality rate (%)

Number

Bilcke 2011 [21]

Belgium

1990-2007

60-70

 

0.06

   

70+

 

0.63

Gonzalez Chiappe 2010 [27]

France

2000-2007

Overall

96.8% (1360; 170/year) in those aged ≥65 years

0.286 (0.244-0.328)

0.075

2.012

1 405 (176 ± 13/year)

≥65

 

4.36 ± 0.20

 

45-54

 

0.031 (0–0.069)

0.007

 

55-64

 

0.072 (0.009-0.135)

0.012

 

65-74

 

0.236 (0.102-0.370)

0.027

 

75-84

 

1.25 (0.90-1.60)

0.127

 

85-94

 

7.24 (5.66-8.82)

0.672

 

≥95

 

19.48 (11.50-27.47)

1.356

HFR: Malignancies: 4.236 (449/10 599) HIV/AIDS: 0.357 (26/7 277)

Diabetes: 1.654 (94/5 682)

Blood dyscrasias: 3.907 (82/2 099)

RA: 1.759 (38/2 160)

Malnutrition: 6.196 (64/1 033)

Organ transplant: 0.049 (1/2 023)

Ultsch 2011 [30]

Germany

2007-2008

50-54

73% (n = 48) deaths in ≥80 years

0.02 (0.00-0.10)

0.003

 

1

55-59

0.00 NA

0

 

0

60-64

 

0.02 (0.00-0.13)

0.003

 

1

65-69

 

0.06 (0.01-0.17)

0.005

 

3

70-74

 

0.11 (0.04-0.27)

0.010

 

5

75-79

 

0.30 (0.14-0.57)

0.025

 

9

80-84

 

0.54 (0.28-0.94)

0.043

 

12

85-89

 

1.20 (0.67-1.98)

0.096

 

15

≥90

 

3.86 (2.36-5.96)

0.293

 

20

Overall

 

0.21 (0.16-0.26)

0.022

 

66

van Lier 2010 [31]

Netherlands

2000-2007

≥60

92% deaths occurred in ≥ 75 years

0.59 (estimated with pop ≥60 from Eurostat)

  

Mean 18 deaths/year (range 13–26)

de Melker 2006 [23]

Netherlands

1996-2002

≥75

97% occurred in ≥60 years

1.92 (estimated with pop ≥75 from Eurostat)

  

Mean 18 deaths/year (range 13 to 26)

Mesquita 2013 [28]

Portugal

2000-2010

50-59

76.8 years (SD = 13.6)

  

1.0

17 (total)

60-69

   

0.4

70-79

   

0.8

80-89

   

2.9

90-99

   

3.8

Perez-Sola 2011 [29]

Spain

2000-2006

     

0

Gil 2009 [24]

Spain

1998-2004

50-59

 

0.3

 

3.8

156/year (mean)

60-69

 

0.6

 

3.7

70-79

 

1.5

 

4.5

≥80

 

3.9

 

7.1

Gil-Prieto 2011 [26]

Spain

1998-2004

50-59

   

3.0*/1.1

 

60-69

   

2.7*/1.7

≥70

   

5.3*/2.7

50-59

   

No comorbidity: 1.1

Comorbidity: 3.0

Diabetes: 3.0

COPD: 4.2

CVD: 3.7

60-69

 

No comorbidity: 1.7

Comorbidity: 2.7

Diabetes: 1.9

COPD: 2.7

CVD: 3.4

≥70

 

No comorbidity: 2.7

Comorbidity: 5.3

Diabetes: 5.0

COPD: 5.0

CVD: 5.9

Gil-Prieto 2012 [25]

Spain

1997-2008

First diagnosis

     

≥50§

   

2.51§ (1.42-3.61)/

20

≥50#

   

1.62# (0.67-2.5)

11

50-59

     

60-69

   

0/0

0§/0#

≥70

   

1.16§ (0–0.76)/0#

2§/0#

3.61§ (1.97-6.25)/

18§/11#

2.48# (1.03-3.93)

 

All ages

    

22§/11#

    

1.89§ (1.1-1.27)/

 
    

1.22# (1.9-5.0)

 

Any diagnosis:

     

≥50

    

117§/70#

50-59

    

4§/1#

60-69

    

16§/3#

≥70

    

97§/66#

Brisson 2003 [22]

England & Wales

1991-2000

45-64$

 

0.014

0.002

0.612

2$

≥65$

 

0.566

0.061

3.190

47

all ages$$

 

0.094

0.031

2.722)

49

Edmunds 2001 [2]

England & Wales

1995-1999

≥60

 

2.0 – 4.0

   

50-54

  

0.009

  

55-59

  

0.009

  

60-64

  

0.027

  

65-69

  

0.027

  

70-74

  

0.035

  

75-79

  

0.092

  

80-84

  

0.487

  

≥85

  

2.018

  
  1. *in those with diabetes, COPD and cardiovascular; § all; #immuno-competent; $data from national statistics; $$ HES data base.